Table 2 Baseline patient characteristics
Study | Number (CR/IRA-only) (n) | Male (CR/IRA-only) (%) | Age (CR/IRA-only) (years) | Hypertension (CR/IRA-only) (%) | Diabetes (CR/IRA-only) (%) | Previous MI (CR/IRA-only) (%) | Smoking (CR/IRA-only) (%) |
COMPARE-ACUTE 2017 [7] | 295/590 | 79/76 | 62/61 | 46/48 | 15/16 | 7.5/8.1 | 41/49 |
Hamza et al. 2016 [10] | 50/50 | 82/86 | 56/52 | 26/36 | 100/100 | 10/6 | 72/78 |
DANAMI-3- PRIMULTI 2015 [6] | 314/313 | 80/81 | 64/63 | 41/47 | 9/13 | 5/9 | 51/48 |
PRAGUE − 132,015 [11] | 106/108 | NA | NA | NA | NA | NA | NA |
CvLPRIT 2015 [12] | 150/146 | 85/77 | 64/65 | 37/36 | 13/14 | 4.8/3.6 | 34/37 |
PRAMI 2013 [13] | 234/231 | 76/81 | 62/62 | 40/40 | 15/21 | 8/7 | 50/45 |
Ghani et al. 2012 | 79/40 | 80/81 | 62/61 | 26/43 | 6.3/5.0 | 6.3/4.9 | 44/48 |
Politi et al. 2010 [14] | 130/84 | 77/78 | 65/67 | 57/60 | 23/24 | NA | NA |
HELP AMI 2004 [15] | 52/17 | 88/85 | 64/65 | 37/59 | 12/41 | NA | 67/81 |
Study | Anterior MI (CR/IRA-only) (%) | Procedure time (CR/IRA-only) (min) | Contrast Media (CR/IRA-only) (ml) | Glycoprotein IIb/IIIa Inhibitors (CR/IRA-only) (%) | DES (CR/IRA-only) (years) | ||
COMPARE-ACUTE 2017 [7] | 36/35 | 65/59 | 224/202 | 22/25 | 95/96 | ||
Hamza et al. 2016 [10] | 48/46 | NA | NA | 38/34 | 100/100 | ||
DANAMI-3- PRIMULTI 2015 [6] | 33/36 | 76/42 | 280/170 | 20/23 | 95/93 | ||
PRAGUE − 132,015 [11] | NA | NA | NA | NA | NA | ||
CvLPRIT 2015 [12] | 36/36 | 55/41 | 250/190 | 32/32 | 96/91 | ||
PRAMI 2013 [13] | 29/39 | 63/45 | 300/200 | 79/78 | 63/58 | ||
Ghani et al. 2012 [14] | NA | NA | NA | 45/46 | 23/17 | ||
Politi et al. 2010 [15] | 48/42 | NA | NA | 100/100 | NA | ||
HELP AMI 2004 [16] | 52/59 | 53/69 | 341/242 | 75/82 | 0/0 | ||